nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ADRB3—polycystic ovary syndrome	0.625	0.724	CbGaD
Nadolol—ADRB2—polycystic ovary syndrome	0.237	0.275	CbGaD
Nadolol—Bupranolol—ADRB3—polycystic ovary syndrome	0.00141	0.219	CrCbGaD
Nadolol—Abdominal bloating—Metformin—polycystic ovary syndrome	0.00138	0.142	CcSEcCtD
Nadolol—Respiratory distress—Metformin—polycystic ovary syndrome	0.00104	0.106	CcSEcCtD
Nadolol—Pindolol—ADRB3—polycystic ovary syndrome	0.000929	0.145	CrCbGaD
Nadolol—Pirbuterol—ADRB2—polycystic ovary syndrome	0.000832	0.129	CrCbGaD
Nadolol—Levobunolol—ADRB2—polycystic ovary syndrome	0.000741	0.115	CrCbGaD
Nadolol—Carteolol—ADRB2—polycystic ovary syndrome	0.00063	0.0981	CrCbGaD
Nadolol—Bupranolol—ADRB2—polycystic ovary syndrome	0.000536	0.0834	CrCbGaD
Nadolol—Nasal congestion—Metformin—polycystic ovary syndrome	0.000524	0.0538	CcSEcCtD
Nadolol—Salbutamol—ADRB2—polycystic ovary syndrome	0.000504	0.0784	CrCbGaD
Nadolol—Penbutolol—ADRB2—polycystic ovary syndrome	0.00049	0.0763	CrCbGaD
Nadolol—Lethargy—Metformin—polycystic ovary syndrome	0.000487	0.05	CcSEcCtD
Nadolol—Abdominal distension—Metformin—polycystic ovary syndrome	0.000415	0.0427	CcSEcCtD
Nadolol—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000395	0.0406	CcSEcCtD
Nadolol—Pindolol—ADRB2—polycystic ovary syndrome	0.000353	0.055	CrCbGaD
Nadolol—Bradycardia—Metformin—polycystic ovary syndrome	0.000336	0.0345	CcSEcCtD
Nadolol—Flatulence—Metformin—polycystic ovary syndrome	0.000283	0.0291	CcSEcCtD
Nadolol—Vision blurred—Metformin—polycystic ovary syndrome	0.000271	0.0278	CcSEcCtD
Nadolol—Syncope—Metformin—polycystic ovary syndrome	0.000258	0.0265	CcSEcCtD
Nadolol—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000253	0.026	CcSEcCtD
Nadolol—Hypertension—Metformin—polycystic ovary syndrome	0.000248	0.0255	CcSEcCtD
Nadolol—Chest pain—Metformin—polycystic ovary syndrome	0.000245	0.0251	CcSEcCtD
Nadolol—Oedema—Metformin—polycystic ovary syndrome	0.000235	0.0241	CcSEcCtD
Nadolol—Shock—Metformin—polycystic ovary syndrome	0.000231	0.0237	CcSEcCtD
Nadolol—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000227	0.0233	CcSEcCtD
Nadolol—Anorexia—Metformin—polycystic ovary syndrome	0.000224	0.023	CcSEcCtD
Nadolol—Hypotension—Metformin—polycystic ovary syndrome	0.000219	0.0225	CcSEcCtD
Nadolol—Paraesthesia—Metformin—polycystic ovary syndrome	0.000211	0.0216	CcSEcCtD
Nadolol—Dyspnoea—Metformin—polycystic ovary syndrome	0.000209	0.0215	CcSEcCtD
Nadolol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000206	0.0212	CcSEcCtD
Nadolol—Decreased appetite—Metformin—polycystic ovary syndrome	0.000204	0.0209	CcSEcCtD
Nadolol—Fatigue—Metformin—polycystic ovary syndrome	0.000202	0.0208	CcSEcCtD
Nadolol—Constipation—Metformin—polycystic ovary syndrome	0.000201	0.0206	CcSEcCtD
Nadolol—Asthenia—Metformin—polycystic ovary syndrome	0.000168	0.0173	CcSEcCtD
Nadolol—Pruritus—Metformin—polycystic ovary syndrome	0.000166	0.017	CcSEcCtD
Nadolol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000161	0.0165	CcSEcCtD
Nadolol—Dizziness—Metformin—polycystic ovary syndrome	0.000155	0.0159	CcSEcCtD
Nadolol—Vomiting—Metformin—polycystic ovary syndrome	0.000149	0.0153	CcSEcCtD
Nadolol—Rash—Metformin—polycystic ovary syndrome	0.000148	0.0152	CcSEcCtD
Nadolol—Dermatitis—Metformin—polycystic ovary syndrome	0.000148	0.0152	CcSEcCtD
Nadolol—Nausea—Metformin—polycystic ovary syndrome	0.000139	0.0143	CcSEcCtD
Nadolol—ADRB2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	6.86e-05	0.000564	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	6.84e-05	0.000563	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INHBB—polycystic ovary syndrome	6.79e-05	0.000558	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	6.73e-05	0.000554	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—GHRL—polycystic ovary syndrome	6.49e-05	0.000534	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FLT4—polycystic ovary syndrome	6.41e-05	0.000528	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	6.38e-05	0.000525	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	6.37e-05	0.000524	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—GHRL—polycystic ovary syndrome	6.35e-05	0.000522	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PDE3B—polycystic ovary syndrome	6.33e-05	0.000521	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FLT4—polycystic ovary syndrome	6.27e-05	0.000516	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	6.24e-05	0.000514	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	6.23e-05	0.000512	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—GHRL—polycystic ovary syndrome	6.18e-05	0.000508	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	5.84e-05	0.00048	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—FSHR—polycystic ovary syndrome	5.8e-05	0.000477	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FSHR—polycystic ovary syndrome	5.77e-05	0.000475	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	5.71e-05	0.00047	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—FSHR—polycystic ovary syndrome	5.67e-05	0.000466	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—POMC—polycystic ovary syndrome	5.65e-05	0.000465	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	5.62e-05	0.000462	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—GHRL—polycystic ovary syndrome	5.61e-05	0.000461	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NPB—polycystic ovary syndrome	5.61e-05	0.000461	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—LHB—polycystic ovary syndrome	5.55e-05	0.000457	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	5.5e-05	0.000452	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	5.5e-05	0.000452	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NPB—polycystic ovary syndrome	5.48e-05	0.000451	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—LHB—polycystic ovary syndrome	5.43e-05	0.000447	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	5.43e-05	0.000446	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RACGAP1—polycystic ovary syndrome	5.42e-05	0.000446	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	5.37e-05	0.000442	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	5.31e-05	0.000437	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	5.3e-05	0.000436	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADRA1A—polycystic ovary syndrome	5.28e-05	0.000434	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—SCT—polycystic ovary syndrome	5.2e-05	0.000428	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	5.19e-05	0.000427	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FST—polycystic ovary syndrome	5.14e-05	0.000423	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	5.11e-05	0.000421	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	5.1e-05	0.00042	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—SCT—polycystic ovary syndrome	5.09e-05	0.000419	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	5.07e-05	0.000417	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—LHB—polycystic ovary syndrome	5.04e-05	0.000415	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LHB—polycystic ovary syndrome	5.02e-05	0.000413	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—VEGFA—polycystic ovary syndrome	5e-05	0.000411	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	4.99e-05	0.000411	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—GNAS—polycystic ovary syndrome	4.98e-05	0.00041	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	4.96e-05	0.000408	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	4.96e-05	0.000408	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—LHB—polycystic ovary syndrome	4.93e-05	0.000406	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.93e-05	0.000405	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.91e-05	0.000404	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—GNAS—polycystic ovary syndrome	4.87e-05	0.000401	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	4.86e-05	0.000399	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.82e-05	0.000397	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.75e-05	0.000391	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.74e-05	0.00039	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—SCT—polycystic ovary syndrome	4.73e-05	0.000389	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SCT—polycystic ovary syndrome	4.7e-05	0.000387	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	4.69e-05	0.000385	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.68e-05	0.000385	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.68e-05	0.000385	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.64e-05	0.000382	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—SCT—polycystic ovary syndrome	4.62e-05	0.00038	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.58e-05	0.000376	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.58e-05	0.000376	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.51e-05	0.000371	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.49e-05	0.000369	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.41e-05	0.000363	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGF18—polycystic ovary syndrome	4.41e-05	0.000363	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.4e-05	0.000362	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.38e-05	0.00036	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RBP4—polycystic ovary syndrome	4.37e-05	0.00036	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NMNAT3—polycystic ovary syndrome	4.36e-05	0.000359	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—VEGFA—polycystic ovary syndrome	4.33e-05	0.000356	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.31e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.31e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.28e-05	0.000352	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	4.25e-05	0.000349	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	4.16e-05	0.000342	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	4.13e-05	0.00034	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—YAP1—polycystic ovary syndrome	4.08e-05	0.000336	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	4.04e-05	0.000333	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	4.03e-05	0.000331	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GAB1—polycystic ovary syndrome	4.03e-05	0.000331	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPCAT2—polycystic ovary syndrome	3.99e-05	0.000328	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SUOX—polycystic ovary syndrome	3.99e-05	0.000328	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	3.94e-05	0.000324	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INSR—polycystic ovary syndrome	3.85e-05	0.000317	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.76e-05	0.000309	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ISYNA1—polycystic ovary syndrome	3.71e-05	0.000305	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.68e-05	0.000303	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.67e-05	0.000302	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.66e-05	0.000301	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.6e-05	0.000296	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.59e-05	0.000295	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PGR—polycystic ovary syndrome	3.56e-05	0.000293	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	3.42e-05	0.000282	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	3.35e-05	0.000276	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	3.35e-05	0.000276	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.33e-05	0.000274	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GHRL—polycystic ovary syndrome	3.31e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PLAT—polycystic ovary syndrome	3.31e-05	0.000273	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	3.28e-05	0.00027	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	3.27e-05	0.000269	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.26e-05	0.000268	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.22e-05	0.000265	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—POMC—polycystic ovary syndrome	3.19e-05	0.000263	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ATF1—polycystic ovary syndrome	3.16e-05	0.00026	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	3.15e-05	0.000259	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	3.15e-05	0.000259	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.15e-05	0.000259	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.13e-05	0.000258	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.08e-05	0.000254	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT2—polycystic ovary syndrome	3.07e-05	0.000252	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.06e-05	0.000252	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	3.05e-05	0.000251	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	3.04e-05	0.00025	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.02e-05	0.000248	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	2.99e-05	0.000246	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	2.98e-05	0.000245	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.95e-05	0.000243	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NGFR—polycystic ovary syndrome	2.92e-05	0.00024	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	2.91e-05	0.00024	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.91e-05	0.000239	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—POMC—polycystic ovary syndrome	2.9e-05	0.000238	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PRL—polycystic ovary syndrome	2.89e-05	0.000238	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	2.85e-05	0.000235	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.85e-05	0.000234	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.82e-05	0.000232	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.81e-05	0.000231	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.81e-05	0.000231	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	2.79e-05	0.00023	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.79e-05	0.000229	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.76e-05	0.000227	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.76e-05	0.000227	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.75e-05	0.000226	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.74e-05	0.000226	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	2.73e-05	0.000225	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.66e-05	0.000219	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	2.64e-05	0.000217	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	2.62e-05	0.000215	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	2.61e-05	0.000215	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.61e-05	0.000214	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	2.6e-05	0.000213	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	2.56e-05	0.000211	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.56e-05	0.00021	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GNAS—polycystic ovary syndrome	2.54e-05	0.000209	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	2.54e-05	0.000209	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	2.5e-05	0.000206	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.5e-05	0.000206	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.42e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	2.42e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	2.39e-05	0.000197	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—STAR—polycystic ovary syndrome	2.39e-05	0.000196	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	2.39e-05	0.000196	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NRG1—polycystic ovary syndrome	2.38e-05	0.000196	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	2.37e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	2.34e-05	0.000192	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	2.28e-05	0.000188	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	2.24e-05	0.000184	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.17e-05	0.000179	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.14e-05	0.000176	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	2.14e-05	0.000176	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	2.13e-05	0.000175	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.12e-05	0.000175	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	2.12e-05	0.000174	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.09e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	2.07e-05	0.00017	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS2—polycystic ovary syndrome	2.04e-05	0.000168	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	2.03e-05	0.000167	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	2e-05	0.000165	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LEP—polycystic ovary syndrome	1.99e-05	0.000164	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.97e-05	0.000162	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.97e-05	0.000162	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	1.92e-05	0.000158	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	1.92e-05	0.000158	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.89e-05	0.000156	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.88e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.85e-05	0.000152	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.85e-05	0.000152	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.84e-05	0.000151	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.83e-05	0.000151	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.82e-05	0.00015	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.81e-05	0.000149	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.79e-05	0.000147	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.78e-05	0.000147	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.78e-05	0.000146	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.75e-05	0.000144	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.73e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.72e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	1.72e-05	0.000141	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—POMC—polycystic ovary syndrome	1.71e-05	0.000141	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	1.7e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	1.69e-05	0.000139	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	1.68e-05	0.000138	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	1.68e-05	0.000138	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.65e-05	0.000136	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.65e-05	0.000135	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.65e-05	0.000135	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.63e-05	0.000134	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.62e-05	0.000133	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.61e-05	0.000133	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.56e-05	0.000129	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.56e-05	0.000129	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.51e-05	0.000124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	1.51e-05	0.000124	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.48e-05	0.000121	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.45e-05	0.000119	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.44e-05	0.000118	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.43e-05	0.000118	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.41e-05	0.000116	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.41e-05	0.000116	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.38e-05	0.000114	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.35e-05	0.000111	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.33e-05	0.000109	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.26e-05	0.000104	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.21e-05	9.95e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.18e-05	9.73e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.18e-05	9.73e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.16e-05	9.52e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TH—polycystic ovary syndrome	1.15e-05	9.46e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	1.12e-05	9.2e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.08e-05	8.85e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.06e-05	8.68e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	1.05e-05	8.65e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.03e-05	8.49e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.02e-05	8.36e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	1.01e-05	8.31e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	9.94e-06	8.18e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	9.89e-06	8.13e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	9.78e-06	8.04e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	9.77e-06	8.04e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	9.56e-06	7.87e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	9.56e-06	7.86e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	9.39e-06	7.72e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.29e-06	7.64e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.08e-06	7.47e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	8.94e-06	7.35e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	8.48e-06	6.97e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	7.9e-06	6.5e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	7.48e-06	6.15e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	7.44e-06	6.12e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	7.31e-06	6.02e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	6.41e-06	5.27e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.39e-06	5.25e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—POMC—polycystic ovary syndrome	6.32e-06	5.2e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—INS—polycystic ovary syndrome	6.28e-06	5.17e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.25e-06	5.14e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	4.42e-06	3.63e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	4.32e-06	3.55e-05	CbGpPWpGaD
